PSMA radioligand therapy is associated with significant reductions in PSA levels among select patients with metastatic prostate cancer, suggesting tumor responses. Prostate-specific membrane antigen ...

Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this ...

Using an ARPI or taxane after 177Lu-PSMA-617 can produce a robust PSA response in patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu-PSMA-617) was approved in 2022 for patients with metastatic ...

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an ...

Concomitant G-CSF use in maintaining an efficacious dose and safe delivery of docetaxel in combination with darolutamide in patients with metastatic hormone sensitive prostate cancer (mHSPC): ARASENS, ...

In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen deprivation therapy (ADT) and chemotherapy more than doubled biochemical ...

Prostate-specific membrane antigen (PSMA)-PET appeared to cut the risk for treatment failure by half in patients receiving salvage radiotherapy (RT) after radical prostatectomy, without increasing ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify ...

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a prescription drug that’s used to treat prostate cancer in certain situations. Pluvicto comes as a solution for injection or infusion. Pluvicto is ...